However, clinical trials using GLS inhibitor Telaglenastat (CB-839) combined with the mTOR inhibitor everolimus showed a modest improvement of progression-free survival (PFS) from 1.9 months to 3.8 months while it fails to increase PFS in advanced ccRCC in combination with cabozantinib (33). The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.